4 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
Follow Benign Prostatic Hyperplasia: new trials by email Literature Review of Benign Prostatic Hyperplasia trials Research Report on Benign Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Functional Outcomes After Bilateral, 3D Ultrasound-guided Focal Thermal Ablation of the Prostate Transition Zone, in Patients With Benign Prostatic Hyperplasia-related Obstruction Targeted Microwave Ablation - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 8 | 2024-04-24 | 2026-10-01 |
| Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004), Placebo - Benign Prostatic Hyperplasia | Phase 2 | Terminated | OPKO Health, Inc. | 114 | 2018-02-21 | 2021-09-16 |
| A Study in Men With Benign Prostatic Hyperplasia LY500307, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Eli Lilly and Company | 414 | 2010-04-01 | 2019-04-08 |
| Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia Lonidamine - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Threshold Pharmaceuticals | 240 | 2005-06-01 | 2009-04-29 |
Genital Diseases (4) · Genital Diseases, Male (4) · Male Urogenital Diseases (4) · Prostatic Diseases (4) · Urogenital Diseases (4)
erteberel (1) · lonidamine (1)
Assistance Publique - Hôpitaux de Paris (1) · Eli Lilly and Company (1) · OPKO Health, Inc. (1) · Threshold Pharmaceuticals (1)
United States (3) · France (2) · Australia (1) · Canada (1) · Germany (1) · Greece (1) · Italy (1) · Russia (1)